Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.
Sponsor: Arovella Therapeutics Ltd
Summary
Phase 1 Open-Label Dose-Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ALA-101
Official title: A Phase 1 Open-Label Dose-Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ALA-101, Allogeneic, Off-the-shelf, CD19-directed CAR-iNKT Cells in Patients With CD19+ Non-Hodgkin Lymphoma and Leukemia
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
46
Start Date
2026-08-20
Completion Date
2030-08-30
Last Updated
2026-08-06
Healthy Volunteers
No
Conditions
Interventions
ALA-101
Single IV infusion of ALA-101 post chemotherapy conditioning with Fludarabine and Cyclophosphamide
Locations (5)
St. Vincent's Hospital
Sydney, New South Wales, Australia
Mater Misericordiae Ltd (MML)
Brisbane, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Epworth HealthCare
Richmond, Victoria, Australia